Top

Published in:

01-05-2019 | Original Article

Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea

Authors: Dong Won Byun, Seong-Hwan Moon, Tak Kim, Hae-Hyeog Lee, Hyoung Moo Park, Moo-Il Kang, Yong-Chan Ha, Ho-Yeon Chung, Byung-Koo Yoon, Tae-Young Kim, Soo Uk Chae, Chan Soo Shin, Kyu-Hyun Yang, Jae Hyup Lee, Jae Suk Chang, Sung Hoon Kim, In Joo Kim, Jung-Min Koh, Jung Hwa Jung, Kyong Wook Yi, Jeong Joon Yoo, Dong Jin Chung, Young-Kyun Lee, Hyun-Koo Yoon, Seongbin Hong, Deog-Yoon Kim, Ki Hyun Baek, Hyun-Joo Kim, Young-Joo Kim, Seongsik Kang, Yong-Ki Min

Published in: Journal of Bone and Mineral Metabolism | Issue 3/2019

Abstract

Patient-reported outcomes (PROs) provide practical guides for treatment; however, studies that have evaluated PROs of women in Korea with postmenopausal osteoporosis (PMO) are lacking. This cross-sectional, multi-center (29 nationwide hospitals) study, performed from March 2013 to July 2014, aimed to assess PROs related to treatment satisfaction, medication adherence, and quality of life (QoL) in Korean PMO women using osteoporosis medication for prevention/treatment. Patient demographics, clinical characteristics, treatment patterns, PROs, and experience using medication were collected. The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) (score-range, 0–100; domains: effectiveness, side effects, convenience, global satisfaction), Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) (score-range, 0–8), and EuroQol-5 dimensions questionnaire (index score range, − 0.22 to 1.0; EuroQol visual analog scale score range, 0–100) were used. To investigate factors associated with PROs, linear (treatment satisfaction/QoL) or logistic (medication adherence) regression analyses were conducted. A total of 1804 patients (age, 62 years) were investigated; 60.1% used bisphosphonate, with the majority (67.2%) using weekly medication, 27.8% used daily hormone replacement therapy, and 12.1% used daily selective estrogen receptor modulator. Several patients reported gastrointestinal (GI) events (31.6%) and dental visits due to problems (24.1%) while using medication. Factors associated with the highest OS-MMAS domain scores were convenience and global satisfaction. GI events were associated with non-adherence. TSQM scores for effectiveness, side effects, and GI risk factors were significantly associated with QoL. Our study elaborately assessed the factors associated with PROs of Korean PMO women. Based on our findings, appropriate treatment-related adjustments such as frequency/choice of medications and GI risk management may improve PROs.

Available only for authorised users

Baccaro LF, Conde DM, Costa-Paiva L, Pinto-Neto AM (2015) The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging 10:583–591. https://doi.org/10.2147/CIA.S54614 CrossRefPubMedPubMedCentral

Choi YJ, Oh HJ, Kim DJ, Lee Y, Chung YS (2012) The prevalence of osteoporosis in Korean adults aged 50 years or older and the higher diagnosis rates in women who were beneficiaries of a national screening program: the Korea National Health and Nutrition Examination Survey 2008–2009. J Bone Miner Res 27:1879–1886. https://doi.org/10.1002/jbmr.1635 CrossRef

Anonymous (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650

Wactawski-Wende J (2001) Periodontal diseases and osteoporosis: association and mechanisms. Ann Periodontol 6:197–208. https://doi.org/10.1902/annals.2001.6.1.197 CrossRefPubMed

Watts NB, Manson JE (2017) Osteoporosis and fracture risk evaluation and management: shared decision making in clinical practice. JAMA 317:253–254. https://doi.org/10.1001/jama.2016.19087 CrossRefPubMed

Yoon HK, Park C, Jang S, Jang S, Lee YK, Ha YC (2011) Incidence and mortality following hip fracture in Korea. J Korean Med Sci 26:1087–1092. https://doi.org/10.3346/jkms.2011.26.8.1087 CrossRefPubMedPubMedCentral

Woo C, Gao G, Wade S, Hochberg MC (2010) Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr Med Res Opin 26:1003–1009. https://doi.org/10.1185/03007991003633603 CrossRefPubMed

Patrick ARBM, Losina E, Schousboe JT, Cadarette SM, Mogun H, Solomon DH (2010) The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab 95:3251–3259CrossRefPubMedPubMedCentral

Chapurlat R, Delmas PD (2004) Treatment of postmenopausal osteoporosis. Rev Prat (Traitement de l’osteoporose post-menopausique) 54:2120–2126

10.

Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H, American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive A (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243–1251CrossRefPubMed

11.

Pasion EG, Sivananthan SK, Kung AW, Chen SH, Chen YJ, Mirasol R, Tay BK, Shah GA, Khan MA, Tam F, Hall BJ, Thiebaud D (2007) Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. J Bone Miner Metab 25:105–113. https://doi.org/10.1007/s00774-006-0735-7 CrossRefPubMed

12.

Gennari L, Rotatori S, Bianciardi S, Nuti R, Merlotti D (2016) Treatment needs and current options for postmenopausal osteoporosis. Expert Opin Pharmacother 17:1141–1152. https://doi.org/10.1080/14656566.2016.1176147 CrossRefPubMed

13.

Valderas JM, Kotzeva A, Espallargues M, Guyatt G, Ferrans CE, Halyard MY, Revicki DA, Symonds T, Parada A, Alonso J (2008) The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res 17:179–193. https://doi.org/10.1007/s11136-007-9295-0 CrossRefPubMed

14.

Alan Brookhart JA, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, Solmon DH (2007) Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 120:251–256CrossRefPubMed

15.

Sweileh WM, Ihbesheh MS, Jarar IS, Taha AS, Sawalha AF, Zyoud SH, Jamous RM, Morisky DE (2011) Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav 21:301–305. https://doi.org/10.1016/j.yebeh.2011.04.011 CrossRefPubMed

16.

Zyoud SH, Al-Jabi SW, Sweileh WM, Morisky DE (2013) Relationship of treatment satisfaction to medication adherence: findings from a cross-sectional survey among hypertensive patients in Palestine. Health Qual Life Outcomes 11:191. https://doi.org/10.1186/1477-7525-11-191 CrossRefPubMedPubMedCentral

17.

Miyakoshi N, Kudo D, Hongo M, Kasukawa Y, Ishikawa Y, Shimada Y (2017) Comparison of spinal alignment, muscular strength, and quality of life between women with postmenopausal osteoporosis and healthy volunteers. Osteoporos Int. https://doi.org/10.1007/s00198-017-4184-z CrossRefPubMed

18.

Madureira MM, Ciconelli RM, Pereira RM (2012) Quality of life measurements in patients with osteoporosis and fractures. Clinics (Sao Paulo) 67:1315–1320CrossRef

19.

Baczyk G, Samborski W, Jaracz K (2016) Evaluation of the quality of life of postmenopausal osteoporotic and osteopenic women with or without fractures. Arch Med Sci 12:819–827. https://doi.org/10.5114/aoms.2015.55012 CrossRefPubMed

20.

Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30:213–221. https://doi.org/10.1007/s00296-009-0940-5 CrossRefPubMed

21.

Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638–1644. https://doi.org/10.1007/s00198-006-0166-2 CrossRefPubMed

22.

Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12. https://doi.org/10.1186/1477-7525-2-12 CrossRefPubMedPubMedCentral

23.

Reynolds K, Viswanathan HN, Muntner P, Harrison TN, Cheetham TC, Hsu JW, Gold DT, Silverman S, Grauer A, Morisky DE, O’Malley CD (2014) Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates. Qual Life Res 23:2109–2120. https://doi.org/10.1007/s11136-014-0662-3 CrossRefPubMed

24.

Lee YK, Nam HS, Chuang LH, Kim KY, Yang HK, Kwon IS, Kind P, Kweon SS, Kim YT (2009) South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health 12:1187–1193. https://doi.org/10.1111/j.1524-4733.2009.00579.x CrossRefPubMed

25.

Voko Z, Gaspar K, Inotai A, Horvath C, Bors K, Speer G, Kalo Z (2017) Osteoporotic fractures may impair life as much as the complications of diabetes. J Eval Clin Pract 23:1375–1380. https://doi.org/10.1111/jep.12800 CrossRefPubMed

26.

Kuo SZ, Haftek M, Lai JC (2017) Factors associated with medication non-adherence in patients with end-stage liver disease. Dig Dis Sci 62:543–549. https://doi.org/10.1007/s10620-016-4391-z CrossRefPubMed

27.

Espallargues M, Valderas JM, Alonso J (2000) Provision of feedback on perceived health status to health care professionals: a systematic review of its impact. Med Care 38:175–186CrossRefPubMed

28.

Turbi C, Herrero-Beaumont G, Acebes JC, Torrijos A, Grana J, Miguelez R, Sacristan J, Marin F (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256CrossRefPubMed

29.

Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, Macarios D (2010) Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™. Osteoporos Int 23:733–741

30.

Mulligan R, Sobel S (2005) Osteoporosis: diagnostic testing, interpretation, and correlations with oral health—implications for dentistry. Dent Clin N Am 49:463–484. https://doi.org/10.1016/j.cden.2004.10.005 CrossRefPubMed

31.

Warriner AH, Curtis JR (2009) Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 21:356–362. https://doi.org/10.1097/BOR.0b013e32832c6aa4 CrossRefPubMedPubMedCentral

32.

Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968. https://doi.org/10.1007/s00198-003-1502-4 CrossRefPubMed

33.

Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL (2009) Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 122:961 e7–13. https://doi.org/10.1016/j.amjmed.2008.12.021 CrossRefPubMed

34.

Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008. https://doi.org/10.1007/s00198-004-1652-z CrossRefPubMed

35.

Robitaille J, Yoon PW, Moore CA, Liu T, Irizarry-Delacruz M, Looker AC, Khoury MJ (2008) Prevalence, family history, and prevention of reported osteoporosis in U.S. women. Am J Prev Med 35:47–54. https://doi.org/10.1016/j.amepre.2008.03.027 CrossRefPubMed

36.

Hong SM, Choi WH (2011) Osteoporosis and decrease in bone mineral density have associated with the reduced quality of life. Osteoporosis 9:175–179

37.

Dhillon V, Hurst N, Hannan J, Nuki G (2005) Association of low general health status, measured prospectively by Euroqol EQ5D, with osteoporosis, independent of a history of prior fracture. Osteoporos Int 16:483–489. https://doi.org/10.1007/s00198-004-1705-3 CrossRefPubMed

38.

Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G, Osteoporosis Methodology G, The Osteoporosis Research Advisory G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–523. https://doi.org/10.1210/er.2001-3002 CrossRefPubMed

39.

Rosen CJ (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353:595–603. https://doi.org/10.1056/NEJMcp043801 CrossRefPubMed

40.

Eekman DA, Vis M, Bultink IE, Derikx HJ, Dijkmans BA, Lems WF (2009) Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates. BMC Musculoskelet Disord 10:86. https://doi.org/10.1186/1471-2474-10-86 CrossRefPubMedPubMedCentral

41.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, Group FR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938. https://doi.org/10.1001/jama.296.24.2927 CrossRefPubMed

42.

Huas D, Debiais F, Blotman F, Cortet B, Mercier F, Rousseaux C, Berger V, Gaudin AF, Cotté FE (2010) Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMC Womens Health 10:26. https://doi.org/10.1186/1472-6874-10-26 CrossRefPubMedPubMedCentral

Title: Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea
Authors: Dong Won Byun
Seong-Hwan Moon
Tak Kim
Hae-Hyeog Lee
Hyoung Moo Park
Moo-Il Kang
Yong-Chan Ha
Ho-Yeon Chung
Byung-Koo Yoon
Tae-Young Kim
Soo Uk Chae
Chan Soo Shin
Kyu-Hyun Yang
Jae Hyup Lee
Jae Suk Chang
Sung Hoon Kim
In Joo Kim
Jung-Min Koh
Jung Hwa Jung
Kyong Wook Yi
Jeong Joon Yoo
Dong Jin Chung
Young-Kyun Lee
Hyun-Koo Yoon
Seongbin Hong
Deog-Yoon Kim
Ki Hyun Baek
Hyun-Joo Kim
Young-Joo Kim
Seongsik Kang
Yong-Ki Min
Publication date: 01-05-2019
Publisher: Springer Japan
Published in: Journal of Bone and Mineral Metabolism / Issue 3/2019
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-018-0956-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Bone mineral density loss in ambulatory children with epilepsy in spite of using supplemental vitamin D in Southern Iran: a case–control study

Effect of a 6-week supervised detraining period on bone metabolism markers and their association with ergometrics and components of the hypothalamic–pituitary–gonadal (HPG) axis in professional male soccer players

Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs

PEG10 counteracts signaling pathways of TGF-β and BMP to regulate growth, motility and invasion of SW1353 chondrosarcoma cells

Biodistribution of strontium and barium in the developing and mature skeleton of rats

Umbilical cord mesenchymal stem cell conditioned medium restored the expression of collagen II and aggrecan in nucleus pulposus mesenchymal stem cells exposed to high glucose

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page